Description: Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, it develops tolerogens proteins technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was incorporated in 2011 and is headquartered in Gothenburg, Sweden.
Home Page: www.toleranzia.se
Arvid Wallgrens backe 20
Gothenburg,
413 46
Sweden
Phone:
46 7 63 19 98 98
Officers
| Name | Title |
|---|---|
| Ms. Charlotte Fribert | CEO & Executive Director |
| Ms. Ann-Sofie Taube | Interim Chief Financial Officer |
| Dr. Björn Löwenadler Ph.D. | Chief Business Officer |
| Dr. Vidar Wendel-Hansen M.D., Ph.D. | Chief Medical Officer |
| Mr. Thomas Palsson M.Sc. | Chief Financial Officer (Leave of Absence) |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 4.0552 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0122 |
| Price-to-Sales TTM: | 4.2695 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |